Drug Profile
Beludavimab - GSK/Vir Biotechnology
Alternative Names: GSK-4182137; VIR-7832Latest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator Vir Biotechnology
- Developer Liverpool School of Tropical Medicine; University of Liverpool; University of Southampton; Vir Biotechnology
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 21 Feb 2024 Discontinued - Phase-I/II for COVID-2019 infections (In the elderly, In adults) in South Africa (IV)
- 21 Feb 2024 Discontinued - Phase-II for COVID-2019 infections (In the elderly, In adults) in United Kingdom (IV)
- 21 Feb 2024 Discontinued - Preclinical for COVID-2019 infections (Prevention) in USA (IV)